Published in Scand J Gastroenterol on November 01, 2001
Latent transforming growth factor β-binding protein 4 is downregulated in esophageal cancer via promoter methylation. PLoS One (2013) 0.81
Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas. Cell Oncol (Dordr) (2011) 0.79
Expression and regulation of latent TGF-beta binding protein-1 transcripts and their splice variants in human glomerular endothelial cells. J Korean Med Sci (2005) 0.75
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Regulation of gastric epithelial cell growth by Helicobacter pylori: offdence for a major role of apoptosis. Gastroenterology (1997) 2.39
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet (1994) 2.05
Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. Endoscopy (2012) 2.01
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut (2001) 1.97
Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Gut (1999) 1.97
Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol (1998) 1.89
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy (2006) 1.70
The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol (1998) 1.66
Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut (2008) 1.65
CREB controls LAP/C/EBP beta transcription. Mol Cell Biol (1997) 1.62
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
Pulmonary hypertension after splenectomy? Ann Intern Med (1999) 1.55
Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 1.53
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer (2005) 1.51
Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology (2000) 1.49
Value of magnifying chromoendoscopy and narrow band imaging (NBI) in classifying colorectal polyps: a prospective controlled study. Endoscopy (2007) 1.46
Targeted adenovirus mediated inhibition of NF-κB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. J Control Release (2012) 1.45
Structural organization of the hepatitis B virus minichromosome. J Mol Biol (2001) 1.45
Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy (1996) 1.44
Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A (2000) 1.44
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol (1999) 1.38
NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem (2000) 1.37
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut (2005) 1.34
Interleukin 6 and liver regeneration. Gut (2000) 1.32
Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol (2001) 1.31
GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis (1998) 1.27
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol (2010) 1.27
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology (1994) 1.26
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology (2000) 1.24
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Interleukin-6-induced tethering of STAT3 to the LAP/C/EBPbeta promoter suggests a new mechanism of transcriptional regulation by STAT3. J Biol Chem (2000) 1.23
Correlation of MRI and CT findings with histopathology in hepatic angiomyolipoma. Eur Radiol (2001) 1.22
Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21
Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. Ann Surg (2000) 1.20
Food intake patterns and risk of coronary heart disease: a prospective cohort study examining the use of traditional scoring techniques. Eur J Clin Nutr (2002) 1.19
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother (2001) 1.18
NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol (2000) 1.18
Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol (1998) 1.17
TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1--relevance for concanavalin A-induced hepatitis. J Immunol (2001) 1.13
Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology (1995) 1.13
A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology (1997) 1.13
Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol (2001) 1.12
Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation. Exp Cell Res (1992) 1.11
Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) (2001) 1.10
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Liver transplantation for metastatic neuroendocrine tumors. Ann Surg (1997) 1.09
Ovarian-like stroma in an invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin. A hint concerning its possible histogenesis. Virchows Arch (1998) 1.09
Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer. Gut (2003) 1.09
Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg (2000) 1.06
Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol (1999) 1.06
The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet (2007) 1.06
Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res (1997) 1.05
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat (2009) 1.05
Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology (1999) 1.04
Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut (2004) 1.01
Computer-aided classification of colorectal polyps based on vascular patterns: a pilot study. Endoscopy (2010) 1.01
Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol (2001) 1.01
Nephron-sparing surgery in synchronous bilateral Wilms' tumors. J Pediatr Surg (1999) 1.01
Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol (2000) 1.00
The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem (1999) 1.00
Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol (1991) 0.99
Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem (2007) 0.97
Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology (2001) 0.96
Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factor. Hepatology (1999) 0.96
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg (1996) 0.95
Dissection of the intracellular pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure. J Immunol (2001) 0.95
Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology (1996) 0.94
Autoregulation enables different pathways to control CCAAT/enhancer binding protein beta (C/EBP beta) transcription. J Mol Biol (2001) 0.94
p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J Biol Chem (1999) 0.94
[Malignant epithelioid hemangioendothelioma of the liver - a very rare tumor in children]. Pathologe (1999) 0.94
Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats. Hepatology (1999) 0.94
Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn (2001) 0.93
Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol (2001) 0.92
Value of magnifying endoscopy in classifying colorectal polyps based on vascular pattern. Endoscopy (2009) 0.92
K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut (2001) 0.90
Gene function analysis by amber stop codon suppression: CMBF is a nuclear protein that supports growth and development of Dictyostelium amoebae. J Mol Biol (2001) 0.90
CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut (2005) 0.90
The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology (1999) 0.90
Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection. Hepatology (1998) 0.90
Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem (2000) 0.89
2-acetaminofluorene blocks cell cycle progression after hepatectomy by p21 induction and lack of cyclin E expression. Oncogene (1999) 0.89